Pathophysiological mechanisms and clinical consequences of exposure to new psychoactive substances (“salts”) on a newborn

Background. The usage of new psychoactive substances (NPAS) is increasing every year among various social groups around the world. According to various authors, the use of abused drugs during pregnancy remains at a high level — from 2.8 to 7% of pregnant women. The usage of NPAS, as well as other groups of abused drugs, during pregnancy is fraught with intrauterine multi-organ damage, however, any organ and tissue specificity for NPAS has not been described. In intervention trials conducted on laboratory animals, negative pathophysiological mechanisms triggered by synthetic cathinones have been demonstrated in the form of increased proapoptotic activity, the formation of autophagolysosomes and reactive oxygen intermediates in cells of nervous tissue, and the pro-inflammatory orientation of cells of the immune system.

Case report describes a predominant lesion of the nervous system (developmental brain malformations, damage to the inspiratory center) and the musculoskeletal system (pronounced miotonical syndrome, congenital pathological fractures of the femurs), leading to multiorgan dysfunction, uncontrolled inflammatory response and, as a result, to the development of severe disablement of such children and an increase in the cohort of palliative pediatric patients. In the article, the authors focus on the pathophysiological mechanisms of NPAS for a deeper and more holistic understanding of the pathological process occurring in the body, in order to form and improve the medical judgment of specialist doctors and cite their own clinical observation as an illustration of the consequences of using NPAS during pregnancy. The authors believe that this review describing the case report is valuable from the point of view of practical applicability both for clinicians of various fields and for researchers.

Conclusion. In addition, it is necessary to pay attention to the fact that the use of NPAS is of great social and economic significance, the description of such clinical observations, as well as in vitro studies, is relevant, and the expansion of ideas about the short-term and long-term negative consequences of the use of NPAS should serve as an initiating stage for the development of rehabilitation strategies for these patients

1. Palamar JJ, Su MK, Hoffman RS. Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011–2014. Am J Drug Alcohol Abuse. 2016;42(1):39–47. doi: https://doi.org/10.3109/00952990.2015.1106551

2. Wood KE. Exposure to bath salts and synthetic tetrahydrocannabinol from 2009 to 2012 in the United States. J Pediatr. 2013;163(1):213–216. doi: https://doi.org/10.1016/j.jpeds.2012.12.056

3. Ebrahim SH, Gfroerer J. Pregnancy-related substance use in the United States during 1996-1998. Obstet Gynecol. 2003;101(2):374–379. doi: https://doi.org/10.1016/s0029-7844(02)02588-7

4. Greenfield SF, Manwani SG, Nargiso JE. Epidemiology of substance use disorders in women. Obstet Gynecol Clin North Am. 2003;30(3):413–446. doi: https://doi.org/10.1016/s0889-8545(03)00072-x

5. Chang JC, Holland CL, Tarr JA, et al. Perinatal Illicit Drug and Marijuana Use. Am J Health Promot. 2017;31(1):35–42. doi: https://doi.org/10.4278/ajhp.141215-QUAL-625

6. Gómez-Ruiz LM, Marchei E, Rotolo MC, et al. Prevalence of Licit and Illicit Drugs Use during Pregnancy in Mexican Women. Pharmaceuticals (Basel). 2022;15(3):382. doi: https://doi.org/10.3390/ph15030382

7. Gunn JK, Rosales CB, Center KE, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open. 2016;6(4):e009986. doi: https://doi.org/10.1136/bmjopen-2015-009986

8. Marchand G, Masoud AT, Govindan M, et al. Birth Outcomes of Neonates Exposed to Marijuana in Utero: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022;5(1):e2145653. doi: https://doi.org/10.1001/jamanetworkopen.2021.45653

9. Reece AS, Hulse GK. Epidemiological overview of multidimensional chromosomal and genome toxicity of cannabis exposure in congenital anomalies and cancer development. Sci Rep. 2021;11(1):13892. doi: https://doi.org/10.1038/s41598-021-93411-5

10. Kalix P. A constituent of khat leaves with amphetamine-like releasing properties. Eur J Pharmacol. 1980;68(2):213–215. doi: https://doi.org/10.1016/0014-2999(80)90326-x

11. den Hollander B, Sundström M, Pelander A, et al. Keto amphetamine toxicity-focus on the redox reactivity of the cathinone designer drug mephedrone. Toxicol Sci. 2014;141(1):120–131. doi: https://doi.org/10.1093/toxsci/kfu108

12. López-Arnau R, Martínez-Clemente J, Rodrigo T, et al. Neuronal changes and oxidative stress in adolescent rats after repeated exposure to mephedrone. Toxicol Appl Pharmacol. 2015;286(1):27–35. doi: https://doi.org/10.1016/j.taap.2015.03.015

13. Buzhdygan TP, Rodrigues CR, McGary HM, et al. The psychoactive drug of abuse mephedrone differentially disrupts bloodbrain barrier properties. J Neuroinflammation. 2021;18(1):63. doi: https://doi.org/10.1186/s12974-021-02116-z

14. Martínez-Clemente J, López-Arnau R, Abad S, et al. Dose and time-dependent selective neurotoxicity induced by mephedrone in mice. PLoS One. 2014;9(6):e99002. doi: https://doi.org/10.1371/journal.pone.0099002

15. Tarkowski P, Jankowski K, Budzyńska B, et al. Potential prooxidative effects of single dose of mephedrone in vital organs of mice. Pharmacol Rep. 2018;70(6):1097–1104. doi: https://doi.org/10.1016/j.pharep.2018.05.010

16. Siedlecka-Kroplewska K, Szczerba A, Lipinska A, et al. 3-Fluoromethcathinone, a structural analog of mephedrone, inhibits growth and induces cell cycle arrest in HT22 mouse hippocampal cells. J Physiol Pharmacol. 2014;65(2):241–246

17. Naseri G, Fazel A, Golalipour MJ, et al. Exposure to mephedrone during gestation increases the risk of stillbirth and induces hippocampal neurotoxicity in mice offspring. Neurotoxicol Teratol. 2018;67:10–17. doi: https://doi.org/10.1016/j.ntt.2018.03.001

18. Adám A, Gerecsei LI, Lepesi N, Csillag A. Apoptotic effects of the ‘designer drug’ methylenedioxypyrovalerone (MDPV) on the neonatal mouse brain. Neurotoxicology. 2014;44:231–236. doi: https://doi.org/10.1016/j.neuro.2014.07.004

19. Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol. 2010;22(2):124–131. doi: https://doi.org/10.1016/j.ceb.2009.11.014

20. Yang ZJ, Chee CE, Huang S, Sinicrope F. Autophagy modulation for cancer therapy. Cancer Biol Ther. 2011;11(2):169–176. doi: https://doi.org/10.4161/cbt.11.2.14663

21. Valente MJ, Amaral C, Correia-da-Silva G, et al. Methylone and MDPV activate autophagy in human dopaminergic SH-SY5Y cells: a new insight into the context of β-keto amphetamines-related neurotoxicity. Arch Toxicol. 2017;91(11):3663–3676. doi: https://doi.org/10.1007/s00204-017-1984-z

22. Matsunaga T, Morikawa Y, Kamata K, et al. α-Pyrrolidinononanophenone provokes apoptosis of neuronal cells through alterations in antioxidant properties. Toxicology. 2017;386:93–102. doi: https://doi.org/10.1016/j.tox.2017.05.017

23. Siedlecka-Kroplewska K, Wrońska A, Stasiłojć G, et al. The Designer Drug 3-Fluoromethcathinone Induces Oxidative Stress and Activates Autophagy in HT22 Neuronal Cells. Neurotox Res. 2018;34(3):388–400. doi: https://doi.org/10.1007/s12640-018-9898-y

24. Angoa-Pérez M, Kane MJ, Francescutti DM, et al. Mephedrone, an abused psychoactive component of ‘bath salts’ and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J Neurochem. 2012;120(6):1097–1107. doi: https://doi.org/10.1111/j.1471-4159.2011.07632.x

25. Marusich JA, Gay EA, Stewart DA, Blough BE. Sex differences in inflammatory cytokine levels following synthetic cathinone self-administration in rats. Neurotoxicology. 2022;88:65–78. doi: https://doi.org/10.1016/j.neuro.2021.11.002

26. Kim OH, Jeon KO, Jang EY. Alpha-pyrrolidinopentiothiophenone (α-PVT) activates the TLR-NF-κB-MAPK signaling pathway and proinflammatory cytokine production and induces behavioral sensitization in mice. Pharmacol Biochem Behav. 2022;221:173484. doi: https://doi.org/10.1016/j.pbb.2022.173484

27. Pichini S, Rotolo MC, García J, et al. Neonatal withdrawal syndrome after chronic maternal consumption of 4-methylethcathinone. Forensic Sci Int. 2014;245:e33–e35. doi: https://doi.org/10.1016/j.forsciint.2014.10.027

28. Adamowicz P, Hydzik P. Fetal death associated with the use of 3,4-MDPHP and α-PHP. Clin Toxicol (Phila). 2019;57(2):112–116. doi: https://doi.org/10.1080/15563650.2018.1502443

29. Grapp M, Kaufmann C, Ebbecke M. Toxicological investigation of forensic cases related to the designer drug 3,4-methylenedioxypyrovalerone (MDPV): Detection, quantification and studies on human metabolism by GC-MS. Forensic Sci Int. 2017;273:1–9. doi: https://doi.org/10.1016/j.forsciint.2017.01.021

30. Adamowicz P, Gil D, Skulska A, Tokarczyk B. Analysis of MDPV in blood--determination and interpretation. J Anal Toxicol. 2013;37(5):308–312. doi: https://doi.org/10.1093/jat/bkt025

31. Kalapos MP. 3,4-methylene-dioxy-pyrovalerone (MDPV) epidemic? Orv Hetil. 2011;152(50):2010–2019. doi: https://doi.org/10.1556/OH.2011.29259

32. Strange LG, Kochelek K, Keasling R, et al. The pharmacokinetic profile of synthetic cathinones in a pregnancy model. Neurotoxicol Teratol. 2017;63:9–13. doi: https://doi.org/10.1016/j.ntt.2017.08.001

33. Stewart JL, Meeker JE. Fetal and infant deaths associated with maternal methamphetamine abuse. J Anal Toxicol. 1997;21(6):515–517. doi: https://doi.org/10.1093/jat/21.6.515